Cardio Round-up: Nanoparticles and Stem Cells in the Spotlight – DocWire News

This weeks Round-up looks to the future, as nanoparticles and stem cell-derived cardiac muscle cells get a closer look. More good news for lovers of yogurt, and a smelly but effective treatment for atherosclerosis as well.

Using stem cells extracted from the patients own blood and skin cells, this Japanese research team completed the first-in-human transplant of cardiac muscle cells derived from pluripotent stem cells. The team achieved this by reprogramming them, reverting them to their embryonic-like pluripotent initial state. I hope that (the transplant) will become a medical technology that will save as many people as possible, as Ive seen many lives that I couldnt save, Yoshiki Sawa, a professor in the Osaka University cardiovascular surgery unit, said in apress report.

Stem Cell-Derived Heart Muscle Transplanted Into Human for First Time: Researchers

Like something from a sci-fi horror novel, this team of researcher examined the role that nanoparticles that eat dead cells and stabilize atherosclerotic plaque may be able to play in the future of atherosclerosis treatment. We found we could stimulate the macrophages to selectively eat dead and dying cells these inflammatory cells are precursor cells toatherosclerosis that are part of the cause of heart attacks, one of the authors said in press release. We could deliver a small molecule inside the macrophages to tell them to begin eating again. The authors noted that after a single-cell RNA sequencing analysis, they observed that the prophagocytic nanotubes decreased inflammatory gene expression linked to cytokine and chemokine pathways in lesional macrophages, thereby treating the cell from the inside out.

Are Nanoparticles Potential Gamechangers for Treating Clogged Arteries?

In this large analysis of more than 120,000 individuals, the authors reported multivariable-adjusted hazard ratios (95% CI for all) for mortality were reduced in regular (more than four servings per week) consumers of yogurt, and there was an inverse relationship between regular consumption and cancer mortality as well as cardiovascular-related mortality in women. In our study, regular yogurt consumption was related to lower mortality risk among women, the authors wrote. Given that no clear doseresponse relation was apparent, this result must be interpreted with caution.

Yogurt Consumption Associated with Reduced Mortality Risk (Plus a Caveat)

This research teamlooked human microphages and compared them to dying cells in a dish. They observed that macrophages reclaim arginine and other amino acids when they eat dead cells, and then use an enzyme to convert arginine to putrescine. The putrescine, in return, activates a protein (Rac1) that causes the macrophage to eat more dead cells, suggesting to the authors that the problem of atherosclerosis may be, in part, a problem of putrescine. The findings, according to the accompanying press release, suggest that the compound could be use to potentially treat conditions with chronic inflammation, such as Alzheimers disease.

The Nose Knows: Pungent Compound Associated with Improvements in Atherosclerotic Plaque

Read the rest here:
Cardio Round-up: Nanoparticles and Stem Cells in the Spotlight - DocWire News

Now More Than Just Spine – PRNewswire

ATLANTA, Jan. 31, 2020 /PRNewswire/ --Spine Center Atlanta, founded in 1991 by James Chappuis, MD, FACS, welcomes two new physicians, Brett Rosenberg, MD and Brian Adams, MD. With their addition, Spine Center Atlanta expands its comprehensive patient care platform to include general orthopedic care and interventional pain management, bringing our unique, patient centric program to a wider range of patients.

Dr. Brett Rosenberg, certified by the American Board of Orthopaedic Surgery, earned his medical degree from Thomas Jefferson University Medical College, graduating cum laude. He went on to complete the orthopedic residency program at NYU Langone Hospital.

Dr. Rosenberg brings to Spine Center Atlanta his extensive experience in arthroscopic joint procedures specializing in shoulders and knees as well as total knee replacements, endoscopic carpal tunnel surgery, and fracture care.

Dr. Brian Adams, Spine Interventionalist, has earned a trio of board certifications including Anesthesiology, Interventional Pain Management, and Addiction Medicine. Dr. Adams received a master's degree in Biomedical Engineering from Colorado State University and a Doctorate of Medicine from The Medical College of Georgia followed by an internship and residency with the Department of Anesthesiology at The University of Texas Southwestern. Dr. Adams was recruited by his physician educators to remain for an additional year of advanced level fellowship training in interventional spine procedures and pain management.

When asked about his interventional pain management practice at Spine Center Atlanta, Doctor Adams shared, "So far my experience here has been amazing. We see a population of patients with diverse types and sources of pain, both acute and chronic. It is very rewarding that we are able to successfully treat our patients with state-of-the-art techniques and management."

Both recently appointed physicians' practices are aligned with the Spine Center Atlanta's commitment of, "Getting our patients back to play, back to work, and back to life!"

Beyond our newly expanded practice and treatment options, Spine Center Atlanta provides comprehensive ancillary services including physical therapy, cryotherapy, stem cell treatments, therapeutic massage, and aquatic therapy for patients in our five Georgia locations as well as providing e-consults and travel assistance for patients across the globe.

For more information about Doctors Chappuis, Rosenberg, and Adams and the latest news with Spine Center Atlanta, visit us at https://www.spineatl.com.

SOURCE Spine Center Atlanta

View post:
Now More Than Just Spine - PRNewswire

Does early relapse impact the outcomes of patients with mantle cell lymphoma (MCL)? – Lymphoma Hub

To address these unanswered questions, David A. Bond, The Ohio State University Hospital, Columbus, US, and colleagues conducted a retrospective analysis to evaluate the impact of early relapse on patient outcome in MCL. The data were presented during the 61st American Society of Hematology Meeting & Exposition, Orlando, US.1

Patients with MCL, treated at 12 North American medical centers between 20002017 were retrospectively identified (n= 1,168). In total, 711 patients were excluded from the analysis due to a lack of progression following frontline therapy, or a lack of follow-up data. The remaining patients (n= 457) who experienced relapse were split into three groups based on time to first relapse and treatment intensity*:

* Intensive treatment was defined as high-dose cytarabine-containing induction and/or autologous stem cell transplant (ASCT) in first complete remission (CR1)

Patients in the early relapse groups (PRF and POD24) were generally older (p< 0.001), with a higher frequency of known baseline risk factors including: presence of B symptoms (p< 0.001), a higher MCL International Prognostic Index (MIPI) score (p= 0.001), blastoid morphology (p< 0.001), a Ki67 > 30% (p< 0.001) and a complex karyotype (p= 0.001).

Median follow-up was 2.6 years in surviving patients. Patients who experienced early relapse (PRF and POD24) had a lower secondary median progression-free survival (PFS2) and overall survival (OS) compared to patients with POD> 24 (Table 1). In patients treated with intensive treatment, patients relapsing in < 24 months following induction had a poorer OS. However, OS was improved in patients with POD24 (and POD> 24) following a less intensive frontline treatment. PRF patients had the poorest outcomes.

Table 1. Patient outcomes by POD status

PRF

POD24

POD> 24

p value

Median PFS2 from first relapse, years (95% CI)

1 (0.41.3)

1 (0.81.4)

2.3 (1.83.2)

< 0.0001

OS from first relapse, years (95% CI)

1.3 (0.92.4)

3 (26.8)

8 (6.2NR)

< 0.0001

Patients treated with intensive frontline treatment

OS from first relapse, years (95% CI)

0.9 (0.43)

2 (1.13.4)

9.5 (4.8NR)

< 0.0001

Patients treated with less-intensive frontline treatment

OS from first relapse, years (95% CI)

2 (0.94.5)

6.8 (3.19.7)

10.5 (5.8NR)

< 0.0001

Univariable analysis identified factors associated with mortality (Table 2) which included POD status. Patients in the PRF and POD24 groups had an increased risk of mortality compared with the POD> 24 group.

Table 2. Factors significantly associated with survival in univariable analysis

Factor

Risk of mortality

HR

95% CI

p value

PRF status

Increased

3.77

2.475.77

< 0.001

POD24 status

Increased

2.12

1.532.94

0.002

B symptoms

Increased

1.42

1.021.96

0.036

High MIPI score

Increased

2.47

1.404.36

0.003

Blastoid morphology

Increased

1.93

1.282.91

0.002

Complex karyotype

Increased

2.21

1.124.36

0.022

Rituximab maintenance

Reduced

0.57

0.370.87

0.010

Study investigators conducted multivariable analysis to analyze whether the increased risk in early relapse was present, irrespective of baseline MIPI score and maintenance rituximab. A high MIPI score remained associated with increased risk of death (HR= 2.40; 95% CI, 1.284.50, p= 0.006) and maintenance rituximab was still associated with a reduced risk of death (HR= 0.29; 95% CI, 0.140.58, p< 0.001).

Significantly, early relapse remained a prognostic factor for poor OS:

Given that patients with PRF had the highest risk of early death, their subsequent outcomes were compared by type of second-line treatment. Second-line treatment was lenalidomide and/or bortezomib, chemo-immunotherapy (CIT) or BTK inhibitor (BTKi) (Table 3).

Type of second-line treatment was significant in PRF patients (p= 0.036), with BTKi treatment providing the longest median PFS2. OS was unaffected by second-line treatment (p= 0.546).

Table 3. PFS2 by second-line treatment in patients with PRF disease

Second-line treatment

Median PFS2, years

95% CI

BTKi

1.2

0.52.3

CIT

0.5

0.22.3

Lenalidomide and/or bortezomib

0.3

0.10.6

In this analysis of patients with MCL, a short duration of first remission was associated with an increased risk of death, irrespective of frontline therapy intensity. In patients receiving a less intensive frontline treatment, early mortality was lower in patients who relapsed between six and 24 months following frontline treatment. In patients who relapse very early, BTKi therapy may initially control the disease, but these responses are not durable and novel therapeutic approaches, such as chimeric antigen receptor (CAR) T-cell therapy, are required.

More here:
Does early relapse impact the outcomes of patients with mantle cell lymphoma (MCL)? - Lymphoma Hub

UAMS Professor to Present Relationships Among Food, Health, and Disease in Food Science Seminar – University of Arkansas Newswire

Photo Submitted

Dr. Mahendran Mahadevan, a professor in the Department of Obstetrics and Gynecology at the University of Arkansas for Medical Sciences, willspeakfrom 3-4 p.m. Monday, Feb.3, in Room D2 of the Food Science Building, 2650 N. Young Ave. His presentation, "Food, Health, and Disease,"is open to everyone.

Mahadevan's presentation will focus on how different types of food and beverages plays a role in human body's health defense systems (Angiogenesis, stem cells/regeneration, microbiome, DNA protection, and immunity). This basic biological knowledge related to foods will be useful for better understanding about the effects of foods on the prevention and management of human diseases.

Mahadevan's research interests include: 1) roles of genetics, obesity, nutrition, food supplements, nutraceuticals, physical activity and other environmental/life style factors on prevention/public health and maternal, fetal, and child health; 2) tissue banking; 3) embryo and stem cell culture/expansion (particularly culture medium/conditions); and 4) gene therapy and stem cell gene therapy particularly in cancer and genetic diseases.

Mahadevan received his Veterinary medicine degree in 1975 from University of Ceylon Peradeniya, Sri Lanka and his doctoral degree in Reproductive biology from Monash University, Australia in 1982. His academic experience includes faculty positions in the Department of Physiology, School of medicine at the University of Ceylon and in the Department of Obstetrics and Gynecology at the University of Arkansas for Medical Sciences.

Read more:
UAMS Professor to Present Relationships Among Food, Health, and Disease in Food Science Seminar - University of Arkansas Newswire

Genetic risk scores open a host of concerns and implications – The Daily Cardinal

A world where we can predict what traits and diseases that a baby will be born with is nearly upon us. With the expanding availability of genetic data, researchers in both universities and industry are trying to figure out the complicated relationship between our DNA and human health. For traits and diseases that reflect the interaction between many genetic and oftentimes environmental risk factors, these sorts of predictions are more difficult to make.

Scientists use genome-wide association studies with very large sample sizes to calculate polygenic scores, which correlate genetic factors with complex traits, like height or BMI, and risk for complex diseases, like heart disease or autism.

Almost everything you can think of is highly polygenic meaning [that] many, many, many genes or hundreds of thousands of genetic locations could be affecting [a complex trait], Jason Fletcher, a UW-Madison professor of public affairs studying some of the ethical, legal and social implications of genomic science, said.

Since an individuals genome generally does not change over the course of their lifetime, polygenic scores could offer an avenue for identifying individuals for specialized treatments or early interventions, Fletcher adds.

The positive case might be something like thinking about an instance where there is polygenic score for dyslexia and potentially being able to use a score like that very early in a child's life as a way of collecting individuals who might benefit from specific learning interventions, Fletcher said.

Intellectual disabilities and learning disabilities often go unnoticed for years, which can leave a child to struggle.

Lauren Schmitz, a UW-Madison assistant professor of public affairs, also notes that whereas for heart disease, preventative measures are viewed favorably, for intellectual disability the measures used to intervene would need to be carefully considered to avoid stigmatizing individuals.

Schmitz also stresses that although the science is moving fast, the predictive accuracy of these polygenic risk scores varies depending on the trait or disease in question. However, the for-profit, direct-to-consumer DNA testing industry is blurring the lines on what genomic science can say.

The way I see it, it's the next frontier in personalized things, Schmitz said. I think we're a culture that loves things that are personalized to us me and my experience and so I think the genome is the next marketing frontier.

For example, last November the biotech company Genomic Prediction claimed it could offer polygenic scores for traits including diabetes, heart disease and even IQ as an additional amenity for parents having children through in vitro fertilization. Currently, IVF clinics test fertilized embryos before they are implanted into a uterus to check for inherited genetic disease, like cystic fibrosis or Tays-Sachs disease, or for major chromosome abnormalities that can dramatically decrease the likelihood of a fetus being carried to term.

The announcement has been met with concern from scientists about the accuracy of these new preimplantation tests as well as the long-term effects of selecting on the basis of these traits.

There's all sorts of things where we don't even understand how these different mechanisms are operating and how they're correlated with other aspects of the genome, Schmitz said.

Measurements of intelligence like IQ tests are controversial, and as Angela Saini writes in Superior: The Return of Race Science, much of the work correlating educational attainment with genetics has direct ties to the vestiges of the eugenics movement in the early 20th century. Additionally, for many complex traits and diseases in combination with social and environmental factors at play, these polygenic scores are not necessarily an indication that the trait or disease will manifest.

We should be clear that the scores are not destiny, and there's an upper limit on how predictive it could be, Fletcher said.

Go here to see the original:
Genetic risk scores open a host of concerns and implications - The Daily Cardinal

"Mini Brains" Are Not like the Real Thing – Scientific American

The idea of scientists trying to grow brain tissue in a dish conjures up all sorts of scary mental pictures (cue the horror-movie music). But the reality of the research is quite far from that sci-fi visionand always will be, say researchers in the field. In fact, a leader in this area of research, Arnold Kriegstein of the University of California, San Francisco, says the reality does not measure up to what some scientists make it out to be.

In a paper published on January 29 in Nature, Kriegstein and his colleagues identified which genes were active in 235,000 cells extracted from 37 different organoids and compared them with 189,000 cells from normally developing brains. The organoidsat times called mini brains, to the chagrin of some scientistsare not a fully accurate representation of normal developmental processes, according to the study.

Brain organoids are made from stem cells that are transformed from one cell type to the another until they end up as neurons or other mature cells. But according to the Nature paper, they do not always fully complete this developmental process. Instead the organoids tend to end up with cells that have not fully transformed into new cell typesand they do not re-create the normal brains organizational structure. Psychiatric and neurodevelopmental conditionsincluding schizophrenia and autism, respectivelyand neurodegenerative diseases such as Alzheimers are generally specific to particular cell types and circuits.

Many of the organoid cells showed signs of metabolic stress, the study demonstrated. When the team transplanted organoid cells into mice, their identity became crisper, and they acted more like normal cells, Kriegstein says. This result suggests that the culture conditions under which such cells are grown does not match those of a normally developing brain, he adds. Cellular stress is reversible, Kriegstein says. If we can reverse it, were likely to see the identity of cells improve significantly at the same time.

Brain organoids are getting better at recapitulating the activities of small clusters of neurons, says Kriegstein, who is a professor of neurology and director of the Eli & Edythe Broad Center for Regeneration Medicine and Stem Cell Research at U.C.S.F. Scientists often make organoids from the cells of people with different medical conditions to better understand those conditions. But some scientists may have gone too far in making claims about insights they have derived from patient-specific brain organoids. Id be cautious about that, Kriegstein says. Some of those changes might reflect the abnormal gene expression of the cells and not actually reflect a true disease feature. So thats a problem for scientists to address.

A small ball of cells grown in a dish may be able to re-create some aspects of parts of the brain, but it is not intended to represent the entire brain and its complexity, several researchers have asserted. These organoids are no more sentient than brain tissue removed from a patient during an operation, one scientist has said.

Of course, models are never perfect. Although animal models have led to fundamental insights into brain development, researchers have sought out organoids, or organs-in-a-dish, precisely because of the limitations of extrapolating biological insights from another species to humans. Alzheimers has been cured hundreds of times in mice but never in us, for instance.

That said, the current models are already very useful in addressing some fundamental questions in human brain development, says Hongjun Song, a professor of neuroscience at the Perelman School of Medicine at the University of Pennsylvania, who was not involved in the new research. Using brain organoids, he adds, the Zika virus was recently shown to attack neural stem cells, causing a response that could explain why some babies exposed to Zika in utero develop unusually small brains.

Michael Nestor, a stem cell expert, who did not participate in the new study, says his own organoids are very helpful for identifying unusual activity in brain cells grown from people with autism. And he notes that they will eventually be useful for screening potential drugs.

Even though the models will always be a simplification, the organoid work remains crucial, says PaolaArlotta, chair of the department of stem cell and regenerative biology at Harvard University, who was also not involved in the Nature study. Neuropsychiatric pathologies and neurodevelopmental conditions are generally the result of a large number of genetic changes, which are too complex to be modeled in rodents, she says.

Sergiu Pasca, another leader in the field, says that the cellular stress encountered by Kriegstein and his team might actually be useful in some conditions, helping to create in a dish the kinds of conditions that lead to diseases of neurodegeneration, for instance. What I considerthe most exciting feature remains our ability to derive neural cells and glial cells in vitro, understanding their intrinsic program of maturation in a dish, says Pasca, an assistant professor at Stanford University, who was not part of the new paper.

The ability to improve cell quality when exposed to the environment of the mouse brain suggests that it may be possible to overcome some of the current limitations, Arlotta says. There is not yet a single protocol for making brain organoids in a lab, which may be for the best at this early stage of the field. Eventually, she says, scientists will optimize and standardize the conditions in which these cells are grown.

Arlotta, who is also the Golub Family Professor of Stem Cell and Regenerative Biology at Harvard, published a study last year in Nature showing that she and her colleagues canover a six-month periodmake organoids capable of reliablyincluding a diversity of cell types that are appropriate for the human cerebral cortex. She says it is crucial for organoid work to be done within an ethical framework. Arlotta is part of a federally funded team of bioethicists and scientists working together to ensure that such studies proceed ethically. The scientists educate the bioethicists on the state of the research, she says, and the ethicists inform the scientists about the implications of their work.

Nestor feels so strongly about the importance of linking science, policy and public awareness around stem cell research that he has put his own laboratory at the Hussman Institute for Autism on hold to accept a year-long science-and-technology-policyfellowship with the American Association for the Advancement of Science. He says he took the post to make sure the public and policy makers understand what they need to know about organoids and other cutting-edge science and to learn how to communicate about science with them.

One thing all of the scientists interviewed for this article agree on is that these brain organoids are not actual mini brains, and no one is trying to build a brain in a dish. Even as researchers learn to make more cell types and grow them in more realistic conditions, they will never be able to replicate the brains structure and complexity, Kriegstein says. The exquisite organization of a normal brain is critical to its function, he adds. Brains are still the most complicated structure that nature has ever created.

See the original post here:
"Mini Brains" Are Not like the Real Thing - Scientific American

Consumer Claims Over Peter Thomas Roth’s Alleged "False Advertising" of Skincare Products to Go to Jury – The Fashion Law

A handful of the buzzy products of Peter Thomas Roth are at the center of a strongly-worded lawsuit, one that accuses the New York-based skincare company which boasts about its richly nourishing and technologically advanced offerings of peddling pseudoscience and falsifying the effectiveness of its hyaluronic acid-soaked skin creams and rose stem cell-formulated face masks in an attempt to stand out in the fiercely competitive $135 billion-plus skincare market and cater to the rising demand for anti-aging products among consumers.

According to the complaint that Peter Thomas Roth, LLC (Roth) customers Kari Miller and Samantha Paulson filed in a California state court in December 2018, Roth is running afoul of the law by making false claims about the capabilities of [its] products, at least some of which are among its best-selling products on Sephoras website. The plaintiffs assert that even in an industry known for hype, Roths outrageous marketing practices stand out among those of their competitors, as Roths claims about their [products] are not just hype; rather, they are demonstrably false.

Specifically, Miller and Paulson state that two of Roths product lines,the influencer-endorsed Rose Stem Cell line and the Water Drench line, are at the center of their suit, as both lines have allegedly been marketed and sold in conjunction with false and deceptive representations [about their] active ingredients rose stem cells and hyaluronic acid, respectively that have enabled Roth to profit enormously while its customers are left with overpriced, ineffective skin care products.

For instance the plaintiffs assert that in connection with its Water Drench line of products Roth represents that the active ingredient, hyaluronic acid, will draw moisture from the atmosphere into the users skin, and will hold 1,000 times its weight in water for up to 72 hours. This is impossible, they claim, as hyaluronic acid is incapable of absorbing anywhere near 1,000 times its weight in water, even when it is in its anhydrous (i.e., waterless; completely dry) form.

The judge notes that Roth softened the claim with the words up to in connection with the absorption power of thehyaluronic acid, but he also claims that subtle qualifications do not overcome the thrust of the ad, which is thatthe ad was one thousand times its weight in water.

As for Roths line of Rose Stem Cell products, which the brand claims are are capable of repairing, regenerating, and rejuvenating human skin andstimulating cellular turnoveras a result of the inclusion of rose stem cells, the plaintiffs argue that there is absolutely no evidence thatrosestem cells can provide such benefits. They allege thatRothis clearly attempting to capitalize on the recent media attention that has been given to medical research of human stem cells, with the goal of confusing consumers and causing them to erroneously believe that they will receive significant health benefits by using the Rose Stem Cell Products.

Such pseudo-science has enabled Roth to sell over-priced products to a growing market for skin care products, whileenjoying an unlawful advantage over [its] competitors, the plaintiffs assert in the suit, which has since been transferred from California state court to federal court.

In a couple of recent developments in the case, Judge William Alsup of the U.S. District Court for the Northern District of California denied the plaintiffs bid for class action approval, a move that would enable other individuals who have purchased the allegedly misrepresented products to join in their suit and any ultimate settlement sum. According to Judge Alsups January 22 decision, The plaintiffs can obtain their requested liability determination [for their false advertising claims] and statewide injunction against Roths challenged ads without certifying a class.

Meanwhile, in a separate January 22 order, the judge decided on Roths motion for summary judgment, refusing (for the most part) to issue a final decision resolving the plaintiffs claims ahead of trial because there are still issues of fact to be determined, namely whether Roths marketing claims are deceptive.

According to Judge Alsup, it is unclear how a reasonable consumer might view the marketing claims that Roth uses in connection with its Rose Stem Cell Mask namely, the labels, rose stem cells, cutting edge bio-technology, bio-repair, regenerates, and rejuvenates. While some reasonable consumers might interpret this [language] as mere puffery, and thus, not objective, actionable statements, others could sensibly conclude that rose stem cells actually repair human skin, which the plaintiffs argue is untrue, thereby, making the marketing claims deceptive.

In terms of Roths Water Drench line of products, the judge states that the plaintiffs contend the reasonable consumer would believe that hyaluronic acidactually canattract and retain one thousand times its weight in water, and in fact, a jury could find that, based on the ad, reasonable consumers would expect that hyaluronic acid absorbs and retains about one thousand times its weight in water.As such, these issues must go before a jury, which, Judge Alsup says will look forward to an in-court demonstration in which a certain amount of hyaluronic acid is placed in a beaker, one thousand times that weight in water is placed in another beaker, and the contents are combined, all watching to see if all the water will be absorbed.

*The case is Kari Miller, et al., v. Peter Thomas Roth, LLC, et al.,3:19-cv-00698 (N.D.Cal.)

Read more:
Consumer Claims Over Peter Thomas Roth's Alleged "False Advertising" of Skincare Products to Go to Jury - The Fashion Law

NIH Grants $4.8 Million to Gladstone Institutes to Study ApoE4 in Alzheimer’s – PharmaLive

The best-known genetic marker for Alzheimers disease is ApoE4, a form of apolipoprotein E, which is a protein involved in repairing neurons injured by aging, stroke or other reasons. ApoE4 is found in about a quarter of all people, but in about two-thirds of Alzheimers patients.

The National Institutes of Health (NIH)granted$4.8 million to Robert Mahley, President Emeritus of the Gladstone Instituteslocated in the UCSF Medical Center at Mission Bay, San Francisco. The focus of the research will be to learn more about ApoE4 and how and why it affects Alzheimers disease.

ApoE4 dramatically rewires cellular pathways in neurons and impairs their function, Mahley said. Our goal is to understand how this rewiring occurs and identify potential new treatment strategies to negate the detrimental effects.

Everybody has the ApoE gene, which has three different types, called isoforms: ApoE2, ApoE3 and ApoE4. Researchers at Gladstone have argued for some time that ApoE4 acts as more than a risk factor, directly contributes to brain cell damage. For example, another researcher at Gladstone, Yadong Huang, found that ApoE4 is easily broken into fragments inside neurons, and the fragments impair the function of the neurons.

There are a number of detrimental effects, Mahley said of that research in September 2019. And right now, we have no therapy that targets ApoE4.

The difference between ApoE3 and ApoE4 is a single point mutation, but that change means ApoE4 has a different shape from ApoE3. This makes it more susceptible to the fragmentation.

Our work suggests that these ApoE4 fragments are toxic to neurons and cause sweeping changes to the collection of proteins expressed within a neuron, Mahley said in the most recent announcement. We suspect that their toxicity may underlie much of the neurodegeneration seen in Alzheimers disease.

Mahley plans to use the funds to work with Senior Investigator Nevan Krogan and Gladstone Mass Spectrometry Facility Director Danielle Swaney. They will leverage affinity purification mass spectrometry (AP-MS) to first identify which proteins in a single cell directly interact with ApoE4 fragments.

Swaney said, AP-MS is an important first step because it will allow us to define physical interactions between proteins that may underlie the functional deficits observed in neurons that express ApoE4.

They will be the AP-MS work on neuronal cells derived from mice, which are similar to human neurons. They will also utilize advanced protein analysis to learn more about the abnormal regulation in neurons with ApoE4 being expressed. This will be conducted in neurons from human induced pluripotent stem (hiPS) cells. The procedure for that was developed by Shinya Yamanaka, a 2012 Nobel prize winner and Gladstone senior investigator.

We are quite excited to be involved in this project, Krogan said. My lab has successfully applied AP-MS and other cutting-edge proteomic and genetic techniques to many different diseases, and we now hope to enable a much deeper understanding of ApoE4.

The hope is that by combining that work, they will compile a list of proteins involved in pathways specifically changed in ApoE4 neurons compared to ApoE3 neurons. They will then pick lead candidates for more research in neurons grown from hiPS cells, which will be guided by Yadong Huang.

The plan after that is to use CRISPR gene editing to see if they can reverse the effects of ApoE4 by activating or inhibiting the genes that control their chosen protein candidates.

By the end of the project, we hope to narrow down our list to just a few target genes or proteins that protect or restore neuronal health when we activate or inhibit them in live mice with the ApoE4 gene, Swaney said. They could then be explored as potential targets for Alzheimers treatment in humans.

Read more from the original source:
NIH Grants $4.8 Million to Gladstone Institutes to Study ApoE4 in Alzheimer's - PharmaLive

Judith C. Brings WELCOME TO THE CANCER CAFE to The Marsh Berkeley – Broadway World

A PT Clinical Specialist in Chronic Pain, Judith C. never imagined being on the opposite end of treatment -until she was diagnosed with Multiple Myeloma, an incurable blood cancer with a limited life expectancy. This March, Judith's journey from diagnosis to stem cell transplant unfolds in her hilarious and heartbreaking solo show Welcome to The Cancer Caf at The Marsh Berkeley. Enlightening, elevating, and deeply personal, Judith brings audiences on her unexpected journey from provider to patient, sharing the profound lessons this role reversal offers. Using actual conversations with providers, Judith portrays her interactions with the medical establishment, bringing keen insight and offering a better understanding of the journey and choices faced by people of similar circumstances. Proceeds from each show will be donated to a local cancer organization chosen by Judith.

Talkback engagements after every performance will also be offered. Welcome to The Cancer Caf will be presented March 8 -22, 2020 with performances at 2:00pm Sundays at The Marsh Berkeley, 2120 Allston Way, Berkeley. For tickets ($20-$35 sliding scale; $55 and $100 reserved) or more information, the public may visit http://www.themarsh.org or call The Marsh Box office at 415-282-3055 (open Monday through Friday, 1:00pm-4:00pm).

Motivated by portrayals of cancer heroes, cancer miracles, and people that "fight" for their lives, Judith C. was determined to shed light on different responses to cancer than the typical warrior model. Welcome to The Cancer Caf has been performed at the Stanford Oncology Grand Rounds (2017), Bone Marrow Transplant Life Survivorship Symposium in Denver, CO (2018) and Orlando, FL (2019), Kehilla Community Synagogue (2018), and for various cancer support groups throughout Northern CA. Originally presented at The Marsh Berkley as part of its Marsh Rising series in November 2019, Welcome to The Cancer Caf returns in March 2020 for a full run.

Proceeds from each performance will be donated to a local cancer organization chosen by Judith. Talkback engagements following all performances of Welcome to The Cancer Caf will also be offered:

Sunday, March 8: Proceeds will go towards Camp Kesem (Berkeley), one of many chapters of a wider organization that supports children through and beyond a parent's cancer. Founded at Stanford University in 2000, Camp Kesem has since expanded to 116 chapters in 42 states around the country, offering free summer camps for children who have been impacted by this life-changing event. Camp Kesem Outreach Coordinator Autumn Frlekin and Development Coordinator Shaked Salem will discuss how the camp brings together a community of children with similar experiences in a safe, welcoming environment to have fun and rediscover their childhood.

Sunday, March 15: Charlotte Maxwell Complementary Clinic for Low-Income Women with Cancer in Oakland will be receiving proceeds from the March 15th performance. For 25 years, this free public health clinic and 501(c)(3) non-profit organization has provided integrative cancer care and supportive services that compliment mainstream cancer treatments. These services include acupuncture, herbs, homeopathy, bodywork, guided imagery, movement, and nutritional therapies. Dr. Loveleena Virk and Dr. Divya Chandrasekar, Palliative Care MDs at Kaiser Oakland, will discuss approaches that improve the quality of life of patients and their families facing the problem associated with life-threatening illness.

Sunday, March 22: Proceeds from the final performance will go towards the Women's Cancer Resource Center (WCRC) in Berkeley. This non-profit organization creates opportunities for women with cancer to improve their quality of life through education, supportive services, and practical assistance. Dolores Moorehead, WCRC Lead Client Navigator and Multicultural Client Support Clinician, will be accompanied by a client to share how this organization helps people with cancer navigate through the overwhelming health care system, allowing them to get the appropriate care and treatment they need.

Described by the San Francisco press as "the monologue maestro" and "the dean of solo performance," David Ford has been collaborating on new and unusual theater for decades and has been associated with The Marsh for most of that time. After seeing Welcome to the Cancer Caf, Ford said, "I've worked for 30 years with people who are writing and performing their own stories. In that time, I've heard a lot of people give witness to the trials of having a life-threatening disease. Judith C. goes further than anyone I've ever encountered. She gets the awful contrasts of fear and courage, agency and impotence, armor and vulnerability."

Judith C. (Actor/Writer) is a PT Clinical Specialist in Chronic Pain/Feldenkrais practitioner, with decades of clinical and teaching experience. At age 58, she was diagnosed with Multiple Myeloma, an incurable blood cancer with no clear, accepted treatment path. Following her diagnosis, Judith began writing and performing about her experience as a way to cope with her life as a Myeloma patient being the "new normal" - eventually leading to the birth of her first solo work, Welcome to The Cancer Caf.

Rebecca Fisher (Director) is the creator of The Marsh's Writing Cabaret and the co-producer of the long-running Marsh series Tell it on Tuesday. Her solo performance work has been called "smart, challenging, and unmistakably affecting" by the San Francisco Chronicle and has won a San Francisco Best of Fringe award. She has directed solo shows in national fringe festivals, as well as Mark Kenward's Nantucket and Diane Barnes' My Stroke of Luck, both presented at The Marsh. Fisher was a teaching artist with The Lincoln Center affiliated arts education program in Bay Area schools and has directed theater camps with the Berkeley Playhouse/Julia Morgan Center for the Arts and The Marsh.

The Marsh is known as "a breeding ground for new performance." It was launched in 1989 by Founder and Artistic Director Stephanie Weisman, and now annually hosts more than 600 performances of 175 shows across the company's two venues in San Francisco and Berkeley. A leading outlet for solo performers, The Marsh's specialty has been hailed by the San Francisco Chronicle as "solo performances that celebrate the power of storytelling at its simplest and purest." The East Bay Times named The Marsh one of Bay Area's best intimate theaters, calling it "one of the most thriving solo theaters in the nation. The live theatrical energy is simply irresistible."

The rest is here:
Judith C. Brings WELCOME TO THE CANCER CAFE to The Marsh Berkeley - Broadway World

How does the embryo make all its parts at just the right moments? – Knowable Magazine

In all sorts of animals, from fruit flies to mice to elephants, cells follow fairly similar sets of steps to grow from embryo to adult. But while these steps follow the same order and often involve the same kinds of genes and molecular signals, they proceed at different rates from species to species.

A mouse gestates in about 20 days; a human takes about nine months. An African elephant remains in the womb for nearly two years. And in step with their sizes speaking broadly goes the speed at which cells in their bodies develop.

So what are the timers that keep things trucking along at the right rate for any given organism, ensuring that it grows to the proper size and with all its parts in place? Its a question that James Briscoe, a developmental biologist at the Francis Crick Institute in London, would love to answer.

Take one lone example among many: motor neurons, the nerves that make muscles contract. These develop from precursor cells over a few days in mice but a week or two in humans and the same thing happens when the cells are grown in a dish. We can look at this carefully and demonstrate its the same genetic process, the same gene activities, the same mechanisms involved, and its just running slower in humans than in mouse embryos, Briscoe says. Were trying to tackle that problem.

In a 2018 review published in the journal Development, Briscoe and developmental biologist Miki Ebisuya, now at EMBL Barcelona, explored where the fields understanding of developmental time currently stands. Its a two-part question, Briscoe explains.

First of all, for bodies to properly form, events must unfold in the right sequence: A before B, and B before C, and so on, at right times all over the developing body. Though theres much still to know, scientists have amassed plenty of knowledge on this problem, especially (but not exclusively) in closely studied creatures like the roundworm Caenorhabditis elegans and the fruit fly Drosophila melanogaster.

For example, theres a crisp order in how Drosophila neurons develop from stem cells in a part of the embryo called the ventral nerve cord. The stem cells produce neurons with different identities, one after the other; all of them develop, from the same pool of stem cells, just at different times, and once its time for the later types, theres no going back to making earlier ones. Theyre guided through this process by the sequential rise and fall of activity of a set of key genes.

The second aspect of timing is far more mysterious: the molecular processes setting the tempo such that clocks run faster or slower in different species.

Scientists already have identified types of clocks in sundry tissues. Speaking generally, such molecular timers either count up by steadily increasing the levels of a critical regulator until it exceeds a threshold, or count down by gradually decreasing the levels of an inhibitor, Ebisuya and Briscoe write.

Rats, for instance, use a count up timer to kick off brain-cell development in the embryo. As cells divide, chemicals that inhibit cell division gradually build up in the precursors to types of brain cells called oligodendrocytes. Once the inhibitors reach a key threshold level, the rat brain stops making new precursor cells and existing cells start to take on their mature forms.

In contrast, the African clawed frog Xenopus laevis employs a count down timer at a stage when that frog-to-be is a tiny ball of cells. Substances that spur cell division are diluted by speedy divisions until theyre so scarce that division slows and the next phase of embryo development kicks off.

Some clocks run through feedback loops, wherein proteins build up to a certain level and then act to shut down their production creating cyclical oscillations that cells can harness to drive developmental steps. Vertebrates of all kinds depend on an oscillating clock of this type to create the right number of structures called somites, which later develop into the bones and muscles of the vertebral column. (For more on this segmentation clock, one of the best-studied examples of developmental timing, see this related article in our special report.)

And in other cases, cells seem to keep track of how many times theyve divided, says developmental biologist Mubarak Hussain Syed of the University of New Mexico, who studies the timing of gene activity during Drosophila early brain development. The cell might be counting, OK, we have done 20 divisions, and now its time for the next step, he says.

Despite their strikingly different neck lengths, the giraffe and its nearest relative, the okapi, both have the same number of neck bones, called cervical vertebrae. The vertebrae are merely longer in the giraffe. Scientists believe that changes in the timing of developmental events (slowing down growth of one part relative to another, for example) had a huge part to play in the evolution of species.

CREDIT: ASIANINVASION12 / WIKIMEDIA COMMONS

Whatever the mechanisms, external signals not just clocks inside lone cells are involved to keep everything in step. Drosophila larvae, for example, contain multiple clumps, or discs, of tissue that develop into structures of the adult fly: a pair of discs for the wings, another pair for the eyes, and so on. If one of the wing discs is damaged, scientists observe that development is delayed to give the disc time to repair.

Todays modern technologies, including the ability to culture not just cells but mini-organs in dishes, should yield many clues. One might, for example, be able to add neuronal stem cells from one creature to a mini-brain of another and see if the foreign tissue develops at its own rate or changes its pace to match the cells that surround it, Syed says.

And the findings keep coming. Briscoes team recently posted unpublished results in the online archive BioRxiv suggesting that the difference in the pace of embryonic development of mice and humans may be caused by differences in protein stability between the two species. The differences appear to prolong the duration of the cell cycle in human cells.

Zooming in on details could yield a vast view. Scientists believe that changes in developmental timing heterochronies, as they are called had profound roles to play in the evolution of the diversity in body shapes and proportions we see in modern creatures. Snakes, for example, have many more vertebrae than do mice; they achieve this by running their segmentation clock at a faster clip relative to the development of other body parts. Giraffes come by their long necks another way: They have the same number of cervical vertebrae as their closest relatives, okapi, but those vertebrae are given more time to grow large.

By revealing the molecular clocks that time growth, biologists may start to understand the influences that gave the world mice, humans and elephants to begin with.

More here:
How does the embryo make all its parts at just the right moments? - Knowable Magazine